CoChat

Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Synaptic inhibition is essential for shaping the dynamics of neuronal networks, and aberrant inhibition plays an important role in neurological disorders. Gephyrin is a central player at inhibitory postsynapses, directly binds and organizes GABAA and glycine receptors (GABAARs and GlyRs), and is thereby indispensable for normal inhibitory neurotransmission. Additionally, gephyrin catalyzes the synthesis of the molybdenum cofactor (MoCo) in peripheral tissue. We identified a de novo missense mutation (G375D) in the gephyrin gene (GPHN) in a patient with epileptic encephalopathy resembling Dravet syndrome. Although stably expressed and correctly folded, gephyrin-G375D was non-synaptically localized in neurons and acted dominant-negatively on the clustering of wild-type gephyrin leading to a marked decrease in GABAAR surface expression and GABAergic signaling. We identified a decreased binding affinity between gephyrin-G375D and the receptors, suggesting that Gly375 is essential for gephyrin-receptor complex formation. Surprisingly, gephyrin-G375D was also unable to synthesize MoCo and activate MoCo-dependent enzymes. Thus, we describe a missense mutation that affects both functions of gephyrin and suggest that the identified defect at GABAergic synapses is the mechanism underlying the patient's severe phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201505323

Cites

Statistics

Figures

Figure 1 Localization of the identified GPHN mutation (NM_001024218; NP_001019389) Protein and genetic structure including the different gephyrin domains and genomic location of the gene with an indication of the different exons. The position of the mutation identified in this study is indicated on the protein level, affecting the E‐domain and on the genomic level, affecting exon 12.Multiple alignment of gephyrin and homologous proteins from various species from different kingdoms of life (aligned using Clustal Omega).Co‐crystal structure of gephyrin E‐domain (blue) and bound GlyR β‐loop (red, PDB code 2FTS (Kim et al, 2006)). The mutated gephyrin Gly375 residue is shown in orange.
Figure 1 Localization of the identified GPHN mutation (NM_001024218; NP_001019389) Protein and genetic structure including the different gephyrin domains and genomic location of the gene with an indication of the different exons. The position of the mutation identified in this study is indicated on the protein level, affecting the E‐domain and on the genomic level, affecting exon 12.Multiple alignment of gephyrin and homologous proteins from various species from different kingdoms of life (aligned using Clustal Omega).Co‐crystal structure of gephyrin E‐domain (blue) and bound GlyR β‐loop (red, PDB code 2FTS (Kim et al, 2006)). The mutated gephyrin Gly375 residue is shown in orange.CC BY · PubMed Central
Figure 2 Expression of WT‐gephyrin and gephyrin‐G375D in primary neurons Representative images of GFP‐gephyrin and GFP‐G375D, expressed in hippocampal neurons at 9 + 4 days in vitro. Inset shows higher magnification. Scale bar, 20 μm.Relative distribution of cluster density of gephyrin variants on dendrites from transfected neurons. Number of gephyrin clusters in each dendrite is normalized to 20 μm segments.Representative segments of dendrites expressing GFP‐gephyrin or GFP‐G375D and immunostained with the presynaptic marker VGAT. Arrowheads show co‐localization of gephyrin and VGAT clusters. Scale bar, 10 μm.Quantification of co‐localization between gephyrin and VGAT clusters (gephyrin‐VGAT 77.4 ± 2.9%, G375D‐VGAT 30 ± 4.4%). 31 GFP‐gephyrin and 30 GFP‐G375D neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM and data were analyzed by t‐test.
Figure 2 Expression of WT‐gephyrin and gephyrin‐G375D in primary neurons Representative images of GFP‐gephyrin and GFP‐G375D, expressed in hippocampal neurons at 9 + 4 days in vitro. Inset shows higher magnification. Scale bar, 20 μm.Relative distribution of cluster density of gephyrin variants on dendrites from transfected neurons. Number of gephyrin clusters in each dendrite is normalized to 20 μm segments.Representative segments of dendrites expressing GFP‐gephyrin or GFP‐G375D and immunostained with the presynaptic marker VGAT. Arrowheads show co‐localization of gephyrin and VGAT clusters. Scale bar, 10 μm.Quantification of co‐localization between gephyrin and VGAT clusters (gephyrin‐VGAT 77.4 ± 2.9%, G375D‐VGAT 30 ± 4.4%). 31 GFP‐gephyrin and 30 GFP‐G375D neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM and data were analyzed by t‐test.CC BY · PubMed Central
Figure EV1 Monoclonal 3B11 antibody does not bind to gephyrin‐G375D COS7 cells transfected with GFP‐tagged gephyrin or G375D and immunostained with the monoclonal 3B11 antibody (red). Scale bar, 10 μm.HEK293 cells transfected as in (A) and immunoblotted with GFP‐specific or 3B11 antibodies. Note that 3B11 does not detect G375D in any of these assays.
Figure EV1 Monoclonal 3B11 antibody does not bind to gephyrin‐G375D COS7 cells transfected with GFP‐tagged gephyrin or G375D and immunostained with the monoclonal 3B11 antibody (red). Scale bar, 10 μm.HEK293 cells transfected as in (A) and immunoblotted with GFP‐specific or 3B11 antibodies. Note that 3B11 does not detect G375D in any of these assays.CC BY · PubMed Central
Figure 3 Gephyrin‐G375D acts dominant‐negatively on postsynaptic clustering of WT gephyrin in neurons ARepresentative dendritic segment of a neuron expressing GFP‐G375D and 3B11‐immunostained endogenous gephyrin (red). Scale bar, 5 μm.B, CQuantification of (B) density and (C) size of endogenous gephyrin clusters in neurons expressing GFP, GFP‐G375D, or non‐transfected neighboring neurons. 20 GFP‐G375 and non‐transfected neurons and 15 GFP‐expressing neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM, and data were analyzed by t‐test.
Figure 3 Gephyrin‐G375D acts dominant‐negatively on postsynaptic clustering of WT gephyrin in neurons ARepresentative dendritic segment of a neuron expressing GFP‐G375D and 3B11‐immunostained endogenous gephyrin (red). Scale bar, 5 μm.B, CQuantification of (B) density and (C) size of endogenous gephyrin clusters in neurons expressing GFP, GFP‐G375D, or non‐transfected neighboring neurons. 20 GFP‐G375 and non‐transfected neurons and 15 GFP‐expressing neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM, and data were analyzed by t‐test.CC BY · PubMed Central
Figure 4 Gephyrin‐G375D decreases cell‐surface expression of GABAARs and impairs postsynaptic currents ARepresentative neurons expressing myc‐tagged gephyrin or G375D and pHluorin‐tagged GABAAR γ2. Surface‐expressed γ2 subunits were immunolabeled with GFP antibodies in red, and the pHluorin fluorescence (total γ2 levels) is shown in green.B, CSize (B) and fluorescence (fl.) intensity (C) of surface‐expressed γ2 clusters in myc‐tagged gephyrin and myc‐G375D‐expressing dendrites (n = 20 myc‐gephyrin and 21 myc‐G375D neurons in B and 18 myc‐gephyrin‐ and myc‐G375D neurons in C).DMean γ2‐pHluorin fluorescence in myc‐gephyrin‐ and myc‐G375D‐expressing dendrites (n = 20 myc‐tagged gephyrin‐ and 18 myc‐G375D‐expressing neurons).ENumber of surface γ2 clusters on dendrites normalized to 20 μm segments (n = 18 myc‐tagged gephyrin‐ and myc‐G375D‐expressing neurons).FRepresentative traces of miniature recordings on cultured hippocampal neurons transfected with either GFP‐gephyrin or GFP‐G375D.GmIPSC amplitudes from neurons expressing GFP‐gephyrin or GFP‐G375D (GFP‐gephyrin 53.11 ± 2.8; GFP‐G375D 43.25 ± 2.0 pA). Numbers show analyzed cell numbers. Data (mean +/− SD) were analyzed by one‐way ANOVA and post hoc Tukey test.HFrequency of the mIPSCs from neurons expressing GFP‐gephyrin or GFP‐G375D. The horizontal line within the boxes indicates the median frequency for the represented condition (bottom/top boundary indicates the 25th/75th percentile). Top and bottom error bars indicate the 90th and 10th percentiles, respectively. Analysis by Mann–Whitney test.Data information: In (B–E), at least three independent cultures were used for each experiment and results are expressed as mean ± SEM; data were analyzed by t‐test.
Figure 4 Gephyrin‐G375D decreases cell‐surface expression of GABAARs and impairs postsynaptic currents ARepresentative neurons expressing myc‐tagged gephyrin or G375D and pHluorin‐tagged GABAAR γ2. Surface‐expressed γ2 subunits were immunolabeled with GFP antibodies in red, and the pHluorin fluorescence (total γ2 levels) is shown in green.B, CSize (B) and fluorescence (fl.) intensity (C) of surface‐expressed γ2 clusters in myc‐tagged gephyrin and myc‐G375D‐expressing dendrites (n = 20 myc‐gephyrin and 21 myc‐G375D neurons in B and 18 myc‐gephyrin‐ and myc‐G375D neurons in C).DMean γ2‐pHluorin fluorescence in myc‐gephyrin‐ and myc‐G375D‐expressing dendrites (n = 20 myc‐tagged gephyrin‐ and 18 myc‐G375D‐expressing neurons).ENumber of surface γ2 clusters on dendrites normalized to 20 μm segments (n = 18 myc‐tagged gephyrin‐ and myc‐G375D‐expressing neurons).FRepresentative traces of miniature recordings on cultured hippocampal neurons transfected with either GFP‐gephyrin or GFP‐G375D.GmIPSC amplitudes from neurons expressing GFP‐gephyrin or GFP‐G375D (GFP‐gephyrin 53.11 ± 2.8; GFP‐G375D 43.25 ± 2.0 pA). Numbers show analyzed cell numbers. Data (mean +/− SD) were analyzed by one‐way ANOVA and post hoc Tukey test.HFrequency of the mIPSCs from neurons expressing GFP‐gephyrin or GFP‐G375D. The horizontal line within the boxes indicates the median frequency for the represented condition (bottom/top boundary indicates the 25th/75th percentile). Top and bottom error bars indicate the 90th and 10th percentiles, respectively. Analysis by Mann–Whitney test.Data information: In (B–E), at least three independent cultures were used for each experiment and results are expressed as mean ± SEM; data were analyzed by t‐test.CC BY · PubMed Central
Figure EV2 Gephyrin‐G375D binds to collybistin II leading to the formation of submembranous microclusters in non‐neuronal cells Lysates and co‐immunoprecipitation of HEK293 cell lysates co‐expressing GFP‐tagged gephyrins and mCherry‐tagged collybistin II. GFP‐specific antibodies were used for the immunoprecipitation.Images of COS7 cells (co)‐expressing GFP‐gephyrin or GFP‐G375D with mCherry‐tagged collybistin II (CBII). Note that gephyrin forms large cytoplasmic aggregates (‘blobs’). CBII induces the formation of gephyrin microclusters at the plasma membrane and co‐localizes with the microclusters in both gephyrin variants. Scale bars, 10 μm.Quantification of GFP‐gephyrin and GFP‐G375D microclusters in (co)‐transfected COS7 cells as indicated (microcluster, submembranous localization; 100 cells from two independent transfections were analyzed). Gephyrin in remaining cells either formed blobs or was diffusively distributed. Results are expressed as mean ± SEM and were analyzed using t‐test.
Figure EV2 Gephyrin‐G375D binds to collybistin II leading to the formation of submembranous microclusters in non‐neuronal cells Lysates and co‐immunoprecipitation of HEK293 cell lysates co‐expressing GFP‐tagged gephyrins and mCherry‐tagged collybistin II. GFP‐specific antibodies were used for the immunoprecipitation.Images of COS7 cells (co)‐expressing GFP‐gephyrin or GFP‐G375D with mCherry‐tagged collybistin II (CBII). Note that gephyrin forms large cytoplasmic aggregates (‘blobs’). CBII induces the formation of gephyrin microclusters at the plasma membrane and co‐localizes with the microclusters in both gephyrin variants. Scale bars, 10 μm.Quantification of GFP‐gephyrin and GFP‐G375D microclusters in (co)‐transfected COS7 cells as indicated (microcluster, submembranous localization; 100 cells from two independent transfections were analyzed). Gephyrin in remaining cells either formed blobs or was diffusively distributed. Results are expressed as mean ± SEM and were analyzed using t‐test.CC BY · PubMed Central
Figure 5 Gephyrin‐G375D is stably expressed and oligomerizes with WT‐gephyrin Western blot of HEK293 cells expressing GFP‐tagged gephyrin or G375D using GFP‐specific and polyclonal gephyrin antibodies. Note that both gephyrin variants are stably expressed and show no degradation in the cells. Asterisk in the poly‐gephyrin blot shows endogenous gephyrin.SDS–PAGE of E. coli‐expressed and purified 6His‐tagged gephyrins and CD spectra. Mean residue ellipticity of gephyrin and G375D shows profiles with minima at 208 nm and 222 nm.Size‐exclusion chromatography of purified 6His‐tagged gephyrin and isolated E‐domain variants. Full‐length gephyrins and isolated E‐domains were loaded onto a Superose 6 gel filtration column, and elution of the protein was monitored by measuring absorbance at 280 nm (mAU, milliabsorbance units).Co‐immunoprecipitation of HEK293 cell lysates expressing myc‐tagged gephyrin together with GFP‐tagged gephyrin or G375D using myc‐specific antibodies. Control IgG were used to show specificity of the assay.
Figure 5 Gephyrin‐G375D is stably expressed and oligomerizes with WT‐gephyrin Western blot of HEK293 cells expressing GFP‐tagged gephyrin or G375D using GFP‐specific and polyclonal gephyrin antibodies. Note that both gephyrin variants are stably expressed and show no degradation in the cells. Asterisk in the poly‐gephyrin blot shows endogenous gephyrin.SDS–PAGE of E. coli‐expressed and purified 6His‐tagged gephyrins and CD spectra. Mean residue ellipticity of gephyrin and G375D shows profiles with minima at 208 nm and 222 nm.Size‐exclusion chromatography of purified 6His‐tagged gephyrin and isolated E‐domain variants. Full‐length gephyrins and isolated E‐domains were loaded onto a Superose 6 gel filtration column, and elution of the protein was monitored by measuring absorbance at 280 nm (mAU, milliabsorbance units).Co‐immunoprecipitation of HEK293 cell lysates expressing myc‐tagged gephyrin together with GFP‐tagged gephyrin or G375D using myc‐specific antibodies. Control IgG were used to show specificity of the assay.CC BY · PubMed Central
Figure 6 Gephyrin‐G375D has a significantly decreased binding affinity toward GlyRs and GABAARs Schematic representation of GABAAR α3‐subunit with residues of the cytoplasmic loop that were synthesized and used as a biotinylated peptide for downstream applications. Gephyrin core‐binding motif is shown in red.Representative pull‐down experiment and quantification of 6His‐tagged gephyrin and G375D using immobilized α3‐peptide. 6His‐tagged gephyrin variants were expressed in E. coli cells, purified to homogeneity, and incubated with α3‐peptides immobilized to NeutrAvidin beads. n = 3, normalized to 6His‐tagged gephyrin. 38.9 ± 1.5% G375D were pulled down. Analyzed by t‐test.Representative SPR sensograms of 6His‐gephyrin and 6His‐G375D binding to immobilized GABAAR α3‐peptide. Response units are plotted against time. Injected gephyrin concentrations were 0.5, 2, 10, 25, and 40 μM.SPR binding isotherms of a representative experiment as in (C). Calculated K D values of 3.2 and 10 μM for gephyrin and G375D, respectively, are indicated by vertical lines. The experiment was repeated three times with two independently purified protein batches and two sensor chips.Representative ITC binding isotherms of the cytoplasmic loop of the GlyR β‐subunit (GlyR‐βL, residue 378–426) and 6His‐tagged gephyrin or G375D. The GlyR‐βL‐gephyrin binding data (black) were fitted in a two‐side model, whereas G375D binding could only be fitted to a single binding site. Dissociation constants K D and stoichiometry (N = number of binding sites) are given for each binding component. n = 5 from two independently purified protein batches. Results are expressed as mean ± SEM.
Figure 6 Gephyrin‐G375D has a significantly decreased binding affinity toward GlyRs and GABAARs Schematic representation of GABAAR α3‐subunit with residues of the cytoplasmic loop that were synthesized and used as a biotinylated peptide for downstream applications. Gephyrin core‐binding motif is shown in red.Representative pull‐down experiment and quantification of 6His‐tagged gephyrin and G375D using immobilized α3‐peptide. 6His‐tagged gephyrin variants were expressed in E. coli cells, purified to homogeneity, and incubated with α3‐peptides immobilized to NeutrAvidin beads. n = 3, normalized to 6His‐tagged gephyrin. 38.9 ± 1.5% G375D were pulled down. Analyzed by t‐test.Representative SPR sensograms of 6His‐gephyrin and 6His‐G375D binding to immobilized GABAAR α3‐peptide. Response units are plotted against time. Injected gephyrin concentrations were 0.5, 2, 10, 25, and 40 μM.SPR binding isotherms of a representative experiment as in (C). Calculated K D values of 3.2 and 10 μM for gephyrin and G375D, respectively, are indicated by vertical lines. The experiment was repeated three times with two independently purified protein batches and two sensor chips.Representative ITC binding isotherms of the cytoplasmic loop of the GlyR β‐subunit (GlyR‐βL, residue 378–426) and 6His‐tagged gephyrin or G375D. The GlyR‐βL‐gephyrin binding data (black) were fitted in a two‐side model, whereas G375D binding could only be fitted to a single binding site. Dissociation constants K D and stoichiometry (N = number of binding sites) are given for each binding component. n = 5 from two independently purified protein batches. Results are expressed as mean ± SEM.CC BY · PubMed Central
Figure 7 Gephyrin‐G375D is catalytically inactive and unable to synthesize MoCo Biosynthesis pathway of MoCo with all stable intermediates. Gephyrin G‐ and E‐domain catalyze the last two steps as depicted. In vitro MoCo synthesis assay using 150 pmol purified 6His‐tagged gephyrins. D580A is an activity‐deficient gephyrin mutation previously identified in MoCo‐deficient patients (Reiss et al, 2011). Assays without the addition of gephyrin (‐gephyrin) or molybdenum (‐Mo) served as internal controls of the assay (see also Belaidi & Schwarz, 2013).Experiment as in (B) but with pre‐incubation of 6His‐gephyrin/G375D in a 1:1 ratio to simulate the heterozygous mutation. n = at least 3 with two independently purified protein batches.Data information: Results in (B, C) are expressed as mean ± SEM.
Figure 7 Gephyrin‐G375D is catalytically inactive and unable to synthesize MoCo Biosynthesis pathway of MoCo with all stable intermediates. Gephyrin G‐ and E‐domain catalyze the last two steps as depicted. In vitro MoCo synthesis assay using 150 pmol purified 6His‐tagged gephyrins. D580A is an activity‐deficient gephyrin mutation previously identified in MoCo‐deficient patients (Reiss et al, 2011). Assays without the addition of gephyrin (‐gephyrin) or molybdenum (‐Mo) served as internal controls of the assay (see also Belaidi & Schwarz, 2013).Experiment as in (B) but with pre‐incubation of 6His‐gephyrin/G375D in a 1:1 ratio to simulate the heterozygous mutation. n = at least 3 with two independently purified protein batches.Data information: Results in (B, C) are expressed as mean ± SEM.CC BY · PubMed Central
Figure EV3 Gephyrin‐D580A forms regular postsynaptic clusters in primary neurons ARepresentative dendritic segments of neurons expressing GFP‐gephyrin or GFP‐D580A immunostained with VGAT (red). Note that both gephyrin variants co‐localize with VGAT puncta. Scale bar, 10 μm.B, CQuantification of GFP‐gephyrin cluster size (B) and quantity (C) in hippocampal neurons expressing GFP‐gephyrin or GFP‐D580A. 19 GFP‐gephyrin and 17 GFP‐D580A neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM.
Figure EV3 Gephyrin‐D580A forms regular postsynaptic clusters in primary neurons ARepresentative dendritic segments of neurons expressing GFP‐gephyrin or GFP‐D580A immunostained with VGAT (red). Note that both gephyrin variants co‐localize with VGAT puncta. Scale bar, 10 μm.B, CQuantification of GFP‐gephyrin cluster size (B) and quantity (C) in hippocampal neurons expressing GFP‐gephyrin or GFP‐D580A. 19 GFP‐gephyrin and 17 GFP‐D580A neurons from three independent cultures were used for quantifications. Results are expressed as mean ± SEM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 60 · Cited by 49

Metadata

Authors
Dejanovic, B., Djémié, T., Grünewald, N., Suls, A., Kress, V., Hetsch, F., Craiu, D., Zemel, M., Gormley, P., Lal, D., EuroEPINOMICS Dravet working group, Myers, C. T., Mefford, H. C., Palotie, A., Helbig, I., Meier, J. C., De Jonghe, P., Weckhuysen, S., & Schwarz, G.
Affiliations
  • University of Cologne (DE)
  • University of Antwerp (BE)
  • Technische Universität Braunschweig (DE)
  • Carol Davila University of Medicine and Pharmacy (RO)
  • University of Washington (US)
  • Harvard University (US)
  • Broad Institute (US)
  • Children's Hospital of Philadelphia (US)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
  • Dejanovic, Borislav
  • Weckhuysen, Sarah
Venue
EMBO Molecular Medicine
Published
2015-11-27
Volume
7
Issue
12
Pages
1580-1594
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2179389164
Cited by
49
References
60
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 4
FWCI
2.32
Type
journal article
Language
en
Update notices
erratum (2017-12-01)
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • German Science Foundation (DFG SFB635)
  • Investissements d'avenir (ANR‐10‐IAIHU‐06)
  • Wellcome Trust (089062, 098051)
  • European Commission Framework Programme 7 (FP7) projects (Synsys‐242167, gEUVADIS‐261123)
  • Academy of Finland (251704, 263401)
  • Sigrid Juselius Foundation
  • US NIH (HL113315)
  • Eurocores program EuroEPINOMICS of the European Science Foundation
  • Fund for Scientific Research Flanders
  • University of Antwerp
  • Bundesministerium für Bildung und Forschung BMBF
  • Deutsche Forschungsgemeinschaft DFG Priority Programme (ME2075/7‐1)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
gephyrin, epileptic encephalopathy, Dravet syndrome, GABAergic synapses, GABAA receptor, glycine receptor, synaptic inhibition, dominant negative effect, receptor clustering, GABAergic neurotransmission
MeSH terms
Molybdenum Cofactors, Carrier Proteins, Coenzymes, Epilepsy, Humans, Membrane Proteins, Metalloproteins, Pteridines, Receptors, GABA-A, Synapses, Mutation, Missense

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. https://app.cochat.ai/papers/10.15252/emmm.201505323
The paper
Dejanovic, B., Djémié, T., Grünewald, N., Suls, A., Kress, V., Hetsch, F., Craiu, D., Zemel, M., Gormley, P., Lal, D., EuroEPINOMICS Dravet working group, Myers, C. T., Mefford, H. C., Palotie, A., Helbig, I., Meier, J. C., De Jonghe, P., Weckhuysen, S., & Schwarz, G. (2015). Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201505323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.